Dianthus Therapeutics, Inc. Looking for Director / Senior Director, Financial Planning and Analysis (FP&A) at Waltham, MA Full Time

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies.

On May 3rd, 2023, Dianthus announced it entered into a reverse merger transaction with Magenta Therapeutics, a publicly traded biotech company, to create a new public company with the sole focus on advancing Dianthus’ pipeline of next generation complement therapies. With the cash expected from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have approximately $180 million of cash or cash equivalents immediately post-closing.

Dianthus has a steady cadence of milestones with DNTH103 including top line Phase 1 data aiming to confirm potent classical pathway inhibition and favorable, extended PK expected by the end of 2023, initiation of planned Phase 2 trial in generalized Myasthenia Gravis expected in Q1 2024 followed by two additional planned Phase 2 trial initiations in other neuro indications, and planned initiation of an open label proof of efficacy trial in Cold Agglutinin Disease with patient data expected in 2H 2024.

About The Role

As the Director / Senior Director, FP&A you will have a direct impact on the financial health and forecasting as a growing organization.

Reporting to the CFO, you will be responsible for partnering with departmental leaders to develop and deliver long range planning, budgeting, and serving as a business partner to the organization delivering financial analyses that can be used to evaluate various operational and strategic alternatives. You will work closely with all department heads for reporting needs and projects and have direct interaction with other senior executives, including CEO, CMO and CAO. This is a hands on role and you must have experience building financial models and long-range planning to support our teams, in particular experience working with clinical and CMC teams.

This is an exciting opportunity to join a growing team and have significant impact. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely.

Key Responsibilities

• Support of the annual corporate financial plan for budgeting and forecasting purposes, interfacing directly with senior management and department heads
• Ongoing preparation of, or revision to, long range financial projections in support of assessing corporate initiatives, financing scenarios or other business decisions
• Ensure a high degree of financial budget ownership across the team, providing oversight and training on financial processes
• Assist with valuation analyses (i.e. Discounted Cash Flows) for various strategic corporate objectives, including acquisitions, divestitures, partnering and joint ventures
• Perform variance analyses and other ad-hoc reporting as needed
• Support Executive Leadership Team and Heads of Department with data-driven analysis, presentations and recommendations
• Partner with senior leadership on discrete business development projects
• Identify & lead process improvements

Experience

• Bachelor’s degree in Finance and/or Accounting, preferred
• Experience building financial models and long-range planning to support cross-functional leaders
• Strong strategic and analytical skills, able to envision multiple alternatives for a complex set of business decisions and foster critical evaluations of alternatives
• Ability to use advanced Excel spreadsheet functions and formulas to build and maintain forecast models
• Excellent interpersonal and communication skills
• Demonstrated ability to work with all levels and collaborate with all employees across the organization
• Strong drive, dedication, and work ethic
• Ability to work in a fast-paced, lean environment
• Strong organizational, planning, and follow-up skills and ability to hold others accountable

More About Us

Since raising a $100M Series A in April 2022 co-led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners, Dianthus continues to make progress in advancing its lead monoclonal antibody, DNTH103.

On May 3rd, 2023, Dianthus announced it entered into a reverse merger transaction with Magenta Therapeutics, a publicly traded biotech company, to create a new public company with the sole focus on advancing Dianthus’ pipeline of next generation complement therapies. In support of the merger, Dianthus has secured commitments for a $70 million private investment in its common stock and pre-funded warrants from a syndicate of healthcare investors led by Fidelity Management & Research Company, Catalio Capital Management, 5AM Ventures, Avidity Partners, Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures and Venrock Healthcare Capital Partners, that is expected to close immediately prior to completion of the merger. With the cash expected from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have approximately $180 million of cash or cash equivalents immediately post-closing.